Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targetting ...
The Swiss start-up Chipmind has raised $2.4 million as it builds out a new set of AI agents to accelerate chip design and ...
Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...
News Medical on MSN
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback